TY - JOUR
T1 - Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome
T2 - a double-blind controlled trial
AU - Belch, Jill J. F.
AU - Drury, John K.
AU - Capell, Hilary
AU - Forbes, Charles D.
AU - Newman, Peter
AU - McKenzie, Fiona
AU - Leiberman, Paul
AU - Prentice, Colin R. M.
PY - 1983
Y1 - 1983
N2 - Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.
AB - Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7.5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p less than 0.01). Hand temperature measurements with a thermocouple were significantly improved at 1 week; 6 weeks after the last infusion hand temperatures had returned to baseline. There was a corresponding loss of clinical response 8-10 weeks after the last infusion.
U2 - 10.1016/S0140-6736(83)91624-0
DO - 10.1016/S0140-6736(83)91624-0
M3 - Article
C2 - 6130329
SN - 0140-6736
VL - 1
SP - 313
EP - 315
JO - Lancet
JF - Lancet
IS - 8320
ER -